Table 1 Baseline demographics and disease status in 147 patients with axial spondyloarthritis receiving either standard (NSAID and/or physiotherapy) or TNFα inhibitor therapy
Standard therapy (n= 68) | TNFα inhibitor (n= 79) | |
|---|---|---|
Age | 40.44 (12.86) | 40.29 (10.70) |
Males No (%) | 47 (69%) | 64 (81%) |
Symptom duration | 16.12 (10.62) | 16.94 (9.64) |
BASDAI | 3.71 (2.24) | 5.99 (2.12) |
Total back pain | 3.69 (2.67) | 5.75 (2.57) |
Nocturnal back pain | 4.03 (2.75) | 6.05 (2.60) |
Patient global score | 3.85 (2.57) | 5.91 (2.84) |
BASFI | 2.36 (2.56) | 4.83 (2.71) |
HLA B27a | 55 (87%) | 58 (85%) |
C-reactive protein | 6.83 (9.53) | 18.37 (18.84) |
ASDAS | 2.29 (1.02) | 3.55 (1.10) |
mSASSS | 12.32 (18.15) | 17.47 (19.08) |